{"id":2151,"date":"2026-06-08T12:00:00","date_gmt":"2026-06-08T15:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2151"},"modified":"2026-06-08T12:00:00","modified_gmt":"2026-06-08T15:00:00","slug":"pgrss-prostata-avancada-psma-pluvicto-lu-177-ari-androgenio-receptor-inibidor-cancer-prostata-mhspc-mcrpc","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-prostata-avancada-psma-pluvicto-lu-177-ari-androgenio-receptor-inibidor-cancer-prostata-mhspc-mcrpc\/","title":{"rendered":"PGRSS pr\u00f3stata avan\u00e7ada: PSMA, Pluvicto, ARI"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente desafiada por gestores de centros de oncologia pr\u00f3stata avan\u00e7ada. Em 2026, h\u00e1 uma demanda crescente de hospitais com unidade pr\u00f3stata avan\u00e7ada \u2014 mHSPC metastatic Hormone-Sensitive Prostate Cancer<\/strong> com ADT androgen deprivation therapy LHRH agonista (leuprolide Lupron + goserelin Zoladex + triptorelin Decapeptyl) ou antagonista (degarelix Firmagon + relugolix Orgovyx oral), ARI Androgen Receptor Inhibitor<\/strong> enzalutamida Xtandi Pfizer\/Astellas + abiraterona Zytiga J&J + apalutamida Erleada J&J + darolutamida Nubeqa Bayer Lista C5 R$ 12-30k\/m\u00eas para mHSPC + mCRPC, mCRPC metastatic Castration-Resistant Prostate Cancer<\/strong> com docetaxel Taxotere + cabazitaxel Jevtana + sipuleucel-T Provenge cell therapy + olaparib Lynparza PARP-inhibitor BRCA1\/2+ + rucaparib Rubraca + talazoparib Talzenna, PSMA Prostate-Specific Membrane Antigen PET-CT<\/strong> Ga-68 PSMA-11 + F-18 PSMA-1007 + F-18 DCFPyL Pylarify diagn\u00f3stico estadiamento, Lu-177 PSMA-617 Pluvicto<\/strong> Novartis radiof\u00e1rmaco PRRT R$ 65-120k\/dose \u00d7 4-6 doses ciclo + livro CNEN-NN-3.05 + reten\u00e7\u00e3o 5y + transporte SED para mCRPC PSMA+ p\u00f3s-ARI+chemo, Ra-223 dichloride Xofigo<\/strong> Bayer alfa-emitter para met\u00e1stase \u00f3ssea sintom\u00e1tica Lista C5 R$ 35-65k\/dose \u00d7 6 doses + livro CNEN, brachy pr\u00f3stata HDR Ir-192<\/strong> boost dose + LDR I-125 sementes 80-130 mCi cada 0.4-0.6 mCi para localizado favorable risk + livro CNEN, HIFU High Intensity Focused Ultrasound<\/strong> Sonablate \/ Ablatherm Focal One para pr\u00f3stata localizada focal therapy + criocirurgia, bicalutamida Casodex<\/strong> + flutamida Eulexin + nilutamida Anandron 1\u00aa gera\u00e7\u00e3o antiandrog\u00eanio Lista B + ER Antagonist<\/strong> ER-\u03b1 antagonist mais antigos. A consequ\u00eancia \u00e9 a urg\u00eancia de PGRSS dedicado para pr\u00f3stata avan\u00e7ada<\/strong> \u2014 captura de Lu-177 PSMA-617 Pluvicto<\/strong> Novartis Lista C5 + radioativo R$ 65-120k\/dose \u00d7 4-6 doses = R$ 260-720k\/paciente + livro CNEN-NN-3.05 + reten\u00e7\u00e3o 5y + transporte SED + isolamento radiol\u00f3gico 24-48h + EPI radioprote\u00e7\u00e3o, Ra-223 dichloride Xofigo<\/strong> Bayer alfa-emitter Lista C5 R$ 35-65k\/dose \u00d7 6 doses + livro CNEN + meia-vida 11.4 dias, ARI Lista C5<\/strong> enzalutamida\/abiraterona\/apalutamida\/darolutamida R$ 12-30k\/m\u00eas \u00d7 12-36 meses \u00d7 500-2.000 pacientes mHSPC+mCRPC = R$ 72-1.440M\/ano em ARI, olaparib Lynparza<\/strong> PARP-inhibitor BRCA1\/2 R$ 35-65k\/m\u00eas \u00d7 24 meses + rucaparib Rubraca + talazoparib Talzenna<\/strong> Lista C5, sipuleucel-T Provenge<\/strong> Dendreon dendritic cell vaccine cell therapy R$ 200-300k\/curso \u00d7 3 doses + cadeia fria + monitoriza\u00e7\u00e3o imediata, PSMA-11 \/ DCFPyL Pylarify Ga-68 \/ F-18<\/strong> radiof\u00e1rmaco diagn\u00f3stico R$ 4-12k\/dose CNEN, brachy pr\u00f3stata I-125 sementes 80-130 mCi<\/strong> cada 0.4-0.6 mCi + agulha 18G TRUS-guided + livro CNEN, degarelix Firmagon<\/strong> Ferring + relugolix Orgovyx<\/strong> Myovant LHRH antagonista comprimido oral Lista C5. A realidade \u00e9 que pr\u00f3stata avan\u00e7ada produz RSS de alt\u00edssima complexidade. PGRSS de pr\u00f3stata avan\u00e7ada \u00e9 cadeia integrada<\/strong> \u2014 come\u00e7a no diagn\u00f3stico<\/strong> (PSA + bi\u00f3psia + Gleason + PSMA PET-CT + RM multiparam\u00e9trica), passa pela terapia<\/strong> (ADT + ARI + chemo + Pluvicto + Xofigo) e termina no acompanhamento<\/strong> (PSA + PSMA PET trim + ctDNA AR-V7). O conjunto soma R$ 38.000-78.000\/m\u00eas<\/strong> que muitos gestores subestimam.<\/p>\n

Para o gestor que opera ou planeja unidade pr\u00f3stata avan\u00e7ada, \u00e9 fundamental considerar a complexidade desde o in\u00edcio.<\/p>\n

Os procedimentos pr\u00f3stata avan\u00e7ada e os RSS espec\u00edficos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, a cadeia gera RSS espec\u00edficos.<\/p>\n\n\n\n\n\n\n\n\n\n
Procedimento<\/th>\nInsumo cr\u00edtico<\/th>\nF\u00e1rmaco<\/th>\nRisco RSS<\/th>\n<\/tr>\n<\/thead>\n
ADT LHRH<\/td>\nCaneta SC + frasco<\/td>\nLeuprolide\/goserelin Lista B<\/td>\nA4 + B Lista B<\/td>\n<\/tr>\n
ARI mHSPC\/mCRPC<\/td>\nComprimido oral C5<\/td>\nXtandi\/Zytiga\/Erleada\/Nubeqa<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
Lu-177 PSMA Pluvicto<\/td>\nC\u00e1psula radioativa<\/td>\nLu-177 PSMA-617 R$ 65-120k<\/td>\nA4 + radioativo CNEN<\/td>\n<\/tr>\n
Ra-223 Xofigo<\/td>\nC\u00e1psula alfa-emitter<\/td>\nRadium-223 R$ 35-65k<\/td>\nA4 + radioativo + EPI<\/td>\n<\/tr>\n
Olaparib BRCA+<\/td>\nComprimido oral PARP<\/td>\nLynparza Lista C5 R$ 35-65k\/m\u00eas<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 entre R$ 38.000-78.000\/m\u00eas<\/strong> em PGRSS dedicado de pr\u00f3stata avan\u00e7ada vs R$ 14.000-28.000<\/strong> em PGRSS gen\u00e9rico subdimensionado.<\/p>\n

A ARI + ADT + PARP: o procedimento Lista C5 sist\u00eamico de alt\u00edssimo investimento<\/h2>\n

A primeira camada do desafio \u00e9 o sist\u00eamico. Padr\u00e3o setorial inclui (a) ADT androgen deprivation therapy<\/strong> com LHRH agonista<\/strong> leuprolide Lupron 7.5\/22.5\/45mg trimestral + goserelin Zoladex 3.6\/10.8mg + triptorelin Decapeptyl + antagonista<\/strong> degarelix Firmagon + relugolix Orgovyx oral; (b) ARI 2\u00aa gera\u00e7\u00e3o<\/strong> enzalutamida Xtandi Pfizer\/Astellas + abiraterona Zytiga J&J + apalutamida Erleada J&J + darolutamida Nubeqa Bayer Lista C5 R$ 12-30k\/m\u00eas para mHSPC + mCRPC; (c) chemo<\/strong> docetaxel Taxotere + cabazitaxel Jevtana 2\u00aa linha; (d) PARP-inhibitor<\/strong> olaparib Lynparza AstraZeneca BRCA1\/2+ + rucaparib Rubraca + talazoparib Talzenna Lista C5 R$ 35-65k\/m\u00eas; (e) livro RBI ARI + PARP<\/strong> com cofre + livro 344 + REMS.<\/p>\n

Hospital com 500-2.000 mHSPC\/mCRPC \u00d7 ARI R$ 22k\/m\u00eas \u00d7 24 meses = R$ 264M-1.056M\/ano em ARI + PARP + ADT. Como discutimos no post sobre PGRSS de uro oncol\u00f3gica<\/a>, Lista C5 \u00e9 estruturante.<\/p>\n

O Pluvicto Lu-177 + Xofigo Ra-223: o est\u00e1gio radioativo terap\u00eautico<\/h2>\n

A segunda camada \u00e9 o radioativo. Padr\u00e3o setorial inclui (a) Lu-177 PSMA-617 Pluvicto<\/strong> Novartis radiof\u00e1rmaco PRRT peptide receptor radionuclide therapy R$ 65-120k\/dose \u00d7 4-6 doses = R$ 260-720k\/paciente + livro CNEN-NN-3.05 + reten\u00e7\u00e3o 5y + transporte SED + isolamento radiol\u00f3gico 24-48h + EPI radioprote\u00e7\u00e3o plumb\u00edfera + dos\u00edmetro pessoal; (b) Ra-223 dichloride Xofigo<\/strong> Bayer alfa-emitter Lista C5 R$ 35-65k\/dose \u00d7 6 doses para met\u00e1stase \u00f3ssea sintom\u00e1tica + meia-vida 11.4 dias; (c) PSMA PET-CT diagn\u00f3stico<\/strong> Ga-68 PSMA-11 + F-18 PSMA-1007 + F-18 DCFPyL Pylarify R$ 4-12k\/dose; (d) monitor \u00e1rea RM3000<\/strong> + CoMo-170<\/strong> + dos\u00edmetro pessoal; (e) EPI radioprote\u00e7\u00e3o<\/strong> plumb\u00edfero + capacete + luva + face shield.<\/p>\n

Hospital com 100-300 Pluvictos\/ano \u00d7 R$ 100k m\u00e9dio + 50-150 Xofigos \u00d7 R$ 50k = R$ 12.5-45M\/ano em Pluvicto + Xofigo + livro CNEN.<\/p>\n

A brachy pr\u00f3stata + sipuleucel-T + HIFU: o est\u00e1gio focal+celular<\/h2>\n

A terceira camada \u00e9 o focal+celular. Padr\u00e3o setorial inclui (a) brachy pr\u00f3stata HDR Ir-192<\/strong> boost 8-18Gy\/fra\u00e7\u00e3o + LDR I-125 sementes 80-130 mCi cada 0.4-0.6 mCi via TRUS-guided + agulha 18G + livro CNEN-NN-3.05 + reten\u00e7\u00e3o 5y; (b) sipuleucel-T Provenge<\/strong> Dendreon dendritic cell vaccine cell therapy R$ 200-300k\/curso \u00d7 3 doses + leukapheresis + cadeia fria + monitoriza\u00e7\u00e3o imediata rea\u00e7\u00e3o infusional; (c) HIFU High Intensity Focused Ultrasound<\/strong> Sonablate \/ Ablatherm \/ Focal One para pr\u00f3stata localizada focal therapy + criocirurgia targeted; (d) bicalutamida Casodex<\/strong> + flutamida + nilutamida 1\u00aa gera\u00e7\u00e3o Lista B; (e) PSA + ctDNA AR-V7<\/strong> + biomarker monitoriza\u00e7\u00e3o.<\/p>\n

Hospital com 100-300 brachys + 30-100 Provenge + 50-150 HIFUs\/ano \u00d7 R$ 50-200k = R$ 6-60M\/ano em focal+celular + livro CNEN.<\/p>\n

Tr\u00eas perfis de PGRSS para pr\u00f3stata avan\u00e7ada<\/h2>\n

PGRSS gen\u00e9rico subdimensionado.<\/strong> Sem cobertura espec\u00edfica para Pluvicto + Xofigo + ARI + Provenge. Custo mensal R$ 14.000-28.000<\/strong>, efic\u00e1cia limitada.<\/p>\n

PGRSS dedicado intermedi\u00e1rio.<\/strong> Cobertura para ADT + ARI, sem Pluvicto + Xofigo + PARP. Custo mensal R$ 28.000-52.000<\/strong>, efic\u00e1cia 100-200%.<\/p>\n

PGRSS dedicado completo pr\u00f3stata avan\u00e7ada.<\/strong> ADT + ARI + chemo + Pluvicto + Xofigo + PARP + Provenge + brachy + HIFU + integra\u00e7\u00e3o com PGRSS de uro oncol\u00f3gica<\/a>. Custo mensal R$ 52.000-78.000<\/strong>, ROI 250-500%.<\/p>\n

Os tr\u00eas erros que aparecem em PGRSS pr\u00f3stata avan\u00e7ada subdimensionado<\/h2>\n

O primeiro \u00e9 o subdimensionamento de Pluvicto Lu-177 PSMA-617<\/strong>. R$ 65-120k\/dose \u00d7 4-6 doses + livro CNEN + isolamento radiol\u00f3gico + EPI.<\/p>\n

O segundo \u00e9 a aus\u00eancia de Lista C5 ARI alta volumetria<\/strong>. Xtandi\/Zytiga\/Erleada\/Nubeqa R$ 12-30k\/m\u00eas \u00d7 24 meses \u00d7 500-2.000 pacientes = cofre + livro 344.<\/p>\n

O terceiro \u00e9 a descarte de Ra-223 Xofigo como Grupo D<\/strong>. Alfa-emitter Lista C5 + radioativo + livro CNEN + descarte espec\u00edfico.<\/p>\n

A regula\u00e7\u00e3o de PGRSS no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com pr\u00f3stata avan\u00e7ada como prioridade. As institui\u00e7\u00f5es que estruturam PGRSS dedicado desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBU Sociedade Brasileira de Urologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS de pr\u00f3stata avan\u00e7ada<\/a><\/strong> \u2014 cap\u00edtulo dedicado a ADT LHRH Lupron+Zoladex+Decapeptyl+Firmagon+Orgovyx, ARI Xtandi+Zytiga+Erleada+Nubeqa Lista C5, Pluvicto Lu-177 PSMA-617 Novartis CNEN, Xofigo Ra-223 Bayer, PARP olaparib Lynparza+rucaparib Rubraca+talazoparib Talzenna BRCA+, sipuleucel-T Provenge cell therapy + brachy pr\u00f3stata I-125\/Ir-192.<\/p>\n","protected":false},"excerpt":{"rendered":"

Pr\u00f3stata avan\u00e7ada gera RSS espec\u00edfico \u2014 PSMA, Pluvicto Lu-177, ARI, RT. PGRSS dedicado.<\/p>\n","protected":false},"author":3,"featured_media":2150,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2978,2977,2975,2976],"class_list":["post-2151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-ari","tag-pluvicto","tag-prostata-avancada","tag-psma"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2151"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2151\/revisions"}],"predecessor-version":[{"id":4300,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2151\/revisions\/4300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2150"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}